Analgesic Efficacy of Capsaicin 8% Patch (QUTENZA®) in Coccygodygnia
ConditionCoccyx Disorder
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorNantes University Hospital
About this trial
A retrospective study over a period of 6 years to explore analgesic efficacy of 8% Capsaicin patch (QUTENZA®) in coccygodynic patients, as well as neuropathic predictive factors of therapeutic response.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients who received topical Capsaicin 8% patch therapy for the treatment of their coccygodygnia between August 2016 and August 2022
Disqualifiers
Patients who have already received 8% Capsaicin patch topical treatment in coccyx area.
Trial population
Medical files of 106 patients hospitalized between 2016 and 2022 for persisting coccygodynia (\>3months) and at least one neuropathic symptom in pain expression, and who received capsaicin 8% patch (QUTENZA®) topical treatment.
Trial design
Design model
Case-only
Time perspective
Retrospective
Treatments tested in this trial
Capsaicin
DrugCapsaicin 8% patch (QUTENZA) apposed in coccygeal area
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Responder rate
Success defined by PGIC ≤ 2.
Time frame
3 months after the inclusion visit.Secondary outcomes
1
Therapeutic response neuropathic predictive factors
Identification of baseline neuropathic predictive factors (extracted from DN4 criteria) of Capsaïcine 8% efficacy at 3months (ie. PGIC ≤ 2)
Time frame
3 months after the inclusion visitSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov